Sonja de Munnik
Radboud University Nijmegen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Sonja de Munnik.
European Journal of Human Genetics | 2012
Sonja de Munnik; Louise S. Bicknell; Salim Aftimos; Jumana Y. Al-Aama; Yolande van Bever; Michael B. Bober; Jill Clayton-Smith; Alaa Y. Edrees; Murray Feingold; Alan Fryer; Johanna M. van Hagen; Raoul C. M. Hennekam; Maaike C E Jansweijer; Diana Johnson; Sarina G. Kant; John M. Opitz; A. Radha Ramadevi; Willie Reardon; Alison Ross; Pierre Sarda; Constance T.R.M. Schrander-Stumpel; Jeroen Schoots; I. Karen Temple; Paulien A. Terhal; Annick Toutain; Carol A. Wise; Michael Wright; David L. Skidmore; Mark E. Samuels; Lies H. Hoefsloot
Meier–Gorlin syndrome (MGS) is an autosomal recessive disorder characterized by microtia, patellar aplasia/hypoplasia, and short stature. Recently, mutations in five genes from the pre-replication complex (ORC1, ORC4, ORC6, CDT1, and CDC6), crucial in cell-cycle progression and growth, were identified in individuals with MGS. Here, we report on genotype–phenotype studies in 45 individuals with MGS (27 females, 18 males; age 3 months–47 years). Thirty-five individuals had biallelic mutations in one of the five causative pre-replication genes. No homozygous or compound heterozygous null mutations were detected. In 10 individuals, no definitive molecular diagnosis was made. The triad of microtia, absent/hypoplastic patellae, and short stature was observed in 82% of individuals with MGS. Additional frequent clinical features were mammary hypoplasia (100%) and abnormal genitalia (42%; predominantly cryptorchidism and hypoplastic labia minora/majora). One individual with ORC1 mutations only had short stature, emphasizing the highly variable clinical spectrum of MGS. Individuals with ORC1 mutations had significantly shorter stature and smaller head circumferences than individuals from other gene categories. Furthermore, compared with homozygous missense mutations, compound heterozygous mutations appeared to have a more severe effect on phenotype, causing more severe growth retardation in ORC4 and more frequently pulmonary emphysema in CDT1. A lethal phenotype was seen in four individuals with compound heterozygous ORC1 and CDT1 mutations. No other clear genotype–phenotype association was observed. Growth hormone and estrogen treatment may be of some benefit, respectively, to growth retardation and breast hypoplasia, though further studies in this patient group are needed.
Human Mutation | 2015
Jae-Ran Lee; Myriam Srour; Doyoun Kim; Fadi F. Hamdan; So Hee Lim; Catherine Brunel-Guitton; Jean Claude Décarie; Elsa Rossignol; Grant A. Mitchell; Allison Schreiber; Rocio Moran; Keith Van Haren; Randal Richardson; Joost Nicolai; Karin M E J Oberndorff; Justin D. Wagner; Kym M. Boycott; Elisa Rahikkala; Nella Junna; Henna Tyynismaa; Inge Cuppen; Nienke E. Verbeek; Connie Stumpel; M.A.A.P. Willemsen; Sonja de Munnik; Guy A. Rouleau; Eunjoon Kim; Erik Jan Kamsteeg; Tjitske Kleefstra; Jacques L. Michaud
KIF1A is a neuron‐specific motor protein that plays important roles in cargo transport along neurites. Recessive mutations in KIF1A were previously described in families with spastic paraparesis or sensory and autonomic neuropathy type‐2. Here, we report 11 heterozygous de novo missense mutations (p.S58L, p.T99M, p.G102D, p.V144F, p.R167C, p.A202P, p.S215R, p.R216P, p.L249Q, p.E253K, and p.R316W) in KIF1A in 14 individuals, including two monozygotic twins. Two mutations (p.T99M and p.E253K) were recurrent, each being found in unrelated cases. All these de novo mutations are located in the motor domain (MD) of KIF1A. Structural modeling revealed that they alter conserved residues that are critical for the structure and function of the MD. Transfection studies suggested that at least five of these mutations affect the transport of the MD along axons. Individuals with de novo mutations in KIF1A display a phenotype characterized by cognitive impairment and variable presence of cerebellar atrophy, spastic paraparesis, optic nerve atrophy, peripheral neuropathy, and epilepsy. Our findings thus indicate that de novo missense mutations in the MD of KIF1A cause a phenotype that overlaps with, while being more severe, than that associated with recessive mutations in the same gene.
American Journal of Medical Genetics Part A | 2012
Sonja de Munnik; Barto J. Otten; Jeroen Schoots; Louise S. Bicknell; Salim Aftimos; Jumana Y. Al-Aama; Yolande van Bever; Michael B. Bober; George F. Borm; Jill Clayton-Smith; Cheri Deal; Alaa Y. Edrees; Murray Feingold; Alan Fryer; Johanna M. van Hagen; Raoul C. M. Hennekam; Maaike C E Jansweijer; Diana Johnson; Sarina G. Kant; John M. Opitz; A. Radha Ramadevi; Willie Reardon; Alison Ross; Pierre Sarda; Constance T.R.M. Schrander-Stumpel; A. Erik Sluiter; I. Karen Temple; Paulien A. Terhal; Annick Toutain; Carol A. Wise
Meier–Gorlin syndrome (MGS) is a rare autosomal recessive disorder characterized by primordial dwarfism, microtia, and patellar aplasia/hypoplasia. Recently, mutations in the ORC1, ORC4, ORC6, CDT1, and CDC6 genes, encoding components of the pre‐replication complex, have been identified. This complex is essential for DNA replication and therefore mutations are expected to impair cell proliferation and consequently could globally reduce growth. However, detailed growth characteristics of MGS patients have not been reported, and so this is addressed here through study of 45 MGS patients, the largest cohort worldwide. Here, we report that growth velocity (length) is impaired in MGS during pregnancy and first year of life, but, thereafter, height increases in paralleled normal reference centiles, resulting in a mean adult height of −4.5 standard deviations (SD). Height is dependent on ethnic background and underlying molecular cause, with ORC1 and ORC4 mutations causing more severe short stature and microcephaly. Growth hormone therapy (n = 9) was generally ineffective, though in two patients with significantly reduced IGF1 levels, growth was substantially improved by GH treatment, with 2SD and 3.8 SD improvement in height. Growth parameters for monitoring growth in future MGS patients are provided and as well we highlight that growth is disproportionately affected in certain structures, with growth related minor genital abnormalities (42%) and mammary hypoplasia (100%) frequently present, in addition to established effects on ears and patellar growth.
Human Genetics | 2015
Alma Kuechler; Marjolein H. Willemsen; Beate Albrecht; Carlos A. Bacino; Dennis Bartholomew; Hans van Bokhoven; Marie Jose H. van den Boogaard; Nuria C. Bramswig; Christian Büttner; Kirsten Cremer; Johanna Christina Czeschik; Hartmut Engels; Koen L.I. van Gassen; Elisabeth Graf; Mieke M. van Haelst; Weimin He; Jacob Hogue; Marlies Kempers; David A. Koolen; Glen R. Monroe; Sonja de Munnik; Matthew Pastore; André Reis; Miriam S. Reuter; David Tegay; Joris A. Veltman; Gepke Visser; Peter M. van Hasselt; Eric Smeets; Lisenka E.L.M. Vissers
Recently, de novo heterozygous loss-of-function mutations in beta-catenin (CTNNB1) were described for the first time in four individuals with intellectual disability (ID), microcephaly, limited speech and (progressive) spasticity, and functional consequences of CTNNB1 deficiency were characterized in a mouse model. Beta-catenin is a key downstream component of the canonical Wnt signaling pathway. Somatic gain-of-function mutations have already been found in various tumor types, whereas germline loss-of-function mutations in animal models have been shown to influence neuronal development and maturation. We report on 16 additional individuals from 15 families in whom we newly identified de novo loss-of-function CTNNB1 mutations (six nonsense, five frameshift, one missense, two splice mutation, and one whole gene deletion). All patients have ID, motor delay and speech impairment (both mostly severe) and abnormal muscle tone (truncal hypotonia and distal hypertonia/spasticity). The craniofacial phenotype comprised microcephaly (typically −2 to −4 SD) in 12 of 16 and some overlapping facial features in all individuals (broad nasal tip, small alae nasi, long and/or flat philtrum, thin upper lip vermillion). With this detailed phenotypic characterization of 16 additional individuals, we expand and further establish the clinical and mutational spectrum of inactivating CTNNB1 mutations and thereby clinically delineate this new CTNNB1 haploinsufficiency syndrome.
European Journal of Human Genetics | 2015
Charlotte W. Ockeloen; Marjolein H. Willemsen; Sonja de Munnik; Bregje W.M. van Bon; Nicole de Leeuw; Aad Verrips; Sarina G. Kant; Elizabeth A. Jones; Han G. Brunner; Rosa Laura van Loon; Eric Smeets; Mieke M. van Haelst; Gijs van Haaften; Ann Nordgren; Helena Malmgren; Giedre Grigelioniene; Sascha Vermeer; Pedro Louro; Lina Ramos; T.J.J. Maal; Celeste C van Heumen; Helger G. Yntema; Carine Carels; Tjitske Kleefstra
Loss-of-function variants in ANKRD11 were identified as the cause of KBG syndrome, an autosomal dominant syndrome with specific dental, neurobehavioural, craniofacial and skeletal anomalies. We present the largest cohort of KBG syndrome cases confirmed by ANKRD11 variants reported so far, consisting of 20 patients from 13 families. Sixteen patients were molecularly diagnosed by Sanger sequencing of ANKRD11, one familial case and three sporadic patients were diagnosed through whole-exome sequencing and one patient was identified through genomewide array analysis. All patients were evaluated by a clinical geneticist. Detailed orofacial phenotyping, including orthodontic evaluation, intra-oral photographs and orthopantomograms, was performed in 10 patients and revealed besides the hallmark feature of macrodontia of central upper incisors, several additional dental anomalies as oligodontia, talon cusps and macrodontia of other teeth. Three-dimensional (3D) stereophotogrammetry was performed in 14 patients and 3D analysis of patients compared with controls showed consistent facial dysmorphisms comprising a bulbous nasal tip, upturned nose with a broad base and a round or triangular face. Many patients exhibited neurobehavioural problems, such as autism spectrum disorder or hyperactivity. One-third of patients presented with (conductive) hearing loss. Congenital heart defects, velopharyngeal insufficiency and hip anomalies were less frequent. On the basis of our observations, we recommend cardiac assessment in children and regular hearing tests in all individuals with a molecular diagnosis of KBG syndrome. As ANKRD11 is a relatively common gene in which sequence variants have been identified in individuals with neurodevelopmental disorders, it seems an important contributor to the aetiology of both sporadic and familial cases.
American Journal of Medical Genetics Part A | 2014
Patrick Rump; Nicole de Leeuw; Anthonie J. van Essen; Corien C. Verschuuren-Bemelmans; Hermine E. Veenstra-Knol; Marielle Swinkels; W. Oostdijk; Claudia Ruivenkamp; Willie Reardon; Sonja de Munnik; Mariken Ruiter; Ayala Frumkin; Dorit Lev; Christina Evers; Birgit Sikkema-Raddatz; Trijnie Dijkhuizen; Conny M. A. van Ravenswaaij-Arts
22q11.2 deletion syndrome is one of the most common microdeletion syndromes. Most patients have a deletion resulting from a recombination of low copy repeat blocks LCR22‐A and LCR22‐D. Loss of the TBX1 gene is considered the most important cause of the phenotype. A limited number of patients with smaller, overlapping deletions distal to the TBX1 locus have been described in the literature. In these patients, the CRKL gene is deleted. Haploinsufficiency of this gene has also been implicated in the pathogenesis of 22q11.2 deletion syndrome. To distinguish these deletions (comprising the LCR22‐B to LCR22‐D region) from the more distal 22q11.2 deletions (located beyond LCR22‐D), we propose the term “central 22q11.2 deletions”. In the present study we report on 27 new patients with such a deletion. Together with information on previously published cases, we review the clinical findings of 52 patients. The prevalence of congenital heart anomalies and the frequency of de novo deletions in patients with a central deletion are substantially lower than in patients with a common or distal 22q11.2 deletion. Renal and urinary tract malformations, developmental delays, cognitive impairments and behavioral problems seem to be equally frequent as in patients with a common deletion. None of the patients had a cleft palate. Patients with a deletion that also encompassed the MAPK1 gene, located just distal to LCR22‐D, have a different and more severe phenotype, characterized by a higher prevalence of congenital heart anomalies, growth restriction and microcephaly. Our results further elucidate genotype‐phenotype correlations in 22q11.2 deletion syndrome spectrum.
European Journal of Human Genetics | 2014
Sonja de Munnik; Sixto García-Miñaúr; Alexander Hoischen; Bregje W.M. van Bon; Kym M. Boycott; Jeroen Schoots; Lies H. Hoefsloot; Nine V.A.M. Knoers; Ernie M.H.F. Bongers; Han G. Brunner
The phenotype of patients with a chromosome 1q43q44 microdeletion (OMIM; 612337) is characterized by intellectual disability with no or very limited speech, microcephaly, growth retardation, a recognizable facial phenotype, seizures, and agenesis of the corpus callosum. Comparison of patients with different microdeletions has previously identified ZBTB18 (ZNF238) as a candidate gene for the 1q43q44 microdeletion syndrome. Mutations in this gene have not yet been described. We performed exome sequencing in a patient with features of the 1q43q44 microdeletion syndrome that included short stature, microcephaly, global developmental delay, pronounced speech delay, and dysmorphic facial features. A single de novo non-sense mutation was detected, which was located in ZBTB18. This finding is consistent with an important role for haploinsufficiency of ZBTB18 in the phenotype of chromosome 1q43q44 microdeletions. The corpus callosum is abnormal in mice with a brain-specific knock-out of ZBTB18. Similarly, most (but not all) patients with the 1q43q44 microdeletion syndrome have agenesis or hypoplasia of the corpus callosum. In contrast, the patient with a ZBTB18 point mutation reported here had a structurally normal corpus callosum on brain MRI. Incomplete penetrance or haploinsufficiency of other genes from the critical region may explain the absence of corpus callosum agenesis in this patient with a ZBTB18 point mutation. The findings in this patient with a mutation in ZBTB18 will contribute to our understanding of the 1q43q44 microdeletion syndrome.
Nature Genetics | 2016
Josefine Storm Witteveen; Marjolein H. Willemsen; Thaís C D Dombroski; Nick H M van Bakel; Willy M. Nillesen; Josephus A. van Hulten; Eric J.R. Jansen; Dave Verkaik; Hermine E. Veenstra-Knol; Conny M. A. van Ravenswaaij-Arts; Jolien S. Klein Wassink-Ruiter; Marie Vincent; Albert David; Cédric Le Caignec; Jolanda H. Schieving; Christian Gilissen; Nicola Foulds; Patrick Rump; Tim M. Strom; Kirsten Cremer; Alexander M. Zink; Hartmut Engels; Sonja de Munnik; Jasper E. Visser; Han G. Brunner; Gerard J. M. Martens; Rolph Pfundt; Tjitske Kleefstra; Sharon M. Kolk
Numerous genes are associated with neurodevelopmental disorders such as intellectual disability and autism spectrum disorder (ASD), but their dysfunction is often poorly characterized. Here we identified dominant mutations in the gene encoding the transcriptional repressor and MeCP2 interactor switch-insensitive 3 family member A (SIN3A; chromosome 15q24.2) in individuals who, in addition to mild intellectual disability and ASD, share striking features, including facial dysmorphisms, microcephaly and short stature. This phenotype is highly related to that of individuals with atypical 15q24 microdeletions, linking SIN3A to this microdeletion syndrome. Brain magnetic resonance imaging showed subtle abnormalities, including corpus callosum hypoplasia and ventriculomegaly. Intriguingly, in vivo functional knockdown of Sin3a led to reduced cortical neurogenesis, altered neuronal identity and aberrant corticocortical projections in the developing mouse brain. Together, our data establish that haploinsufficiency of SIN3A is associated with mild syndromic intellectual disability and that SIN3A can be considered to be a key transcriptional regulator of cortical brain development.
PLOS Genetics | 2017
Tom S. Koemans; Tjitske Kleefstra; Melissa C. Chubak; Max H. Stone; Margot R.F. Reijnders; Sonja de Munnik; Marjolein H. Willemsen; Michaela Fenckova; Connie Stumpel; Levinus A. Bok; Margarita Sifuentes Saenz; Kyna A. Byerly; Linda B. Baughn; Alexander P.A. Stegmann; Rolph Pfundt; Huiqing Zhou; Hans van Bokhoven; Annette Schenck; Jamie M. Kramer
Kleefstra syndrome, caused by haploinsufficiency of euchromatin histone methyltransferase 1 (EHMT1), is characterized by intellectual disability (ID), autism spectrum disorder (ASD), characteristic facial dysmorphisms, and other variable clinical features. In addition to EHMT1 mutations, de novo variants were reported in four additional genes (MBD5, SMARCB1, NR1I3, and KMT2C), in single individuals with clinical characteristics overlapping Kleefstra syndrome. Here, we present a novel cohort of five patients with de novo loss of function mutations affecting the histone methyltransferase KMT2C. Our clinical data delineates the KMT2C phenotypic spectrum and reinforces the phenotypic overlap with Kleefstra syndrome and other related ID disorders. To elucidate the common molecular basis of the neuropathology associated with mutations in KMT2C and EHMT1, we characterized the role of the Drosophila KMT2C ortholog, trithorax related (trr), in the nervous system. Similar to the Drosophila EHMT1 ortholog, G9a, trr is required in the mushroom body for short term memory. Trr ChIP-seq identified 3371 binding sites, mainly in the promoter of genes involved in neuronal processes. Transcriptional profiling of pan-neuronal trr knockdown and G9a null mutant fly heads identified 613 and 1123 misregulated genes, respectively. These gene sets show a significant overlap and are associated with nearly identical gene ontology enrichments. The majority of the observed biological convergence is derived from predicted indirect target genes. However, trr and G9a also have common direct targets, including the Drosophila ortholog of Arc (Arc1), a key regulator of synaptic plasticity. Our data highlight the clinical and molecular convergence between the KMT2 and EHMT protein families, which may contribute to a molecular network underlying a larger group of ID/ASD-related disorders.
Journal of Medical Genetics | 2016
Gea Beunders; Jiddeke M. van de Kamp; Pradeep Vasudevan; Jenny Morton; Katrien Smets; Tjitske Kleefstra; Sonja de Munnik; Janneke H M Schuurs-Hoeijmakers; Berten Ceulemans; Marcella Zollino; Sabine Hoffjan; Stefan Wieczorek; Joyce So; Leanne Mercer; Tanya Walker; Lea Velsher; Michael J. Parker; Alex Magee; Bart Elffers; R. Frank Kooy; Helger G. Yntema; Elizabeth J Meijers-Heijboer; Erik A. Sistermans
Background AUTS2 syndrome is an ‘intellectual disability (ID) syndrome’ caused by genomic rearrangements, deletions, intragenic duplications or mutations disrupting AUTS2. So far, 50 patients with AUTS2 syndrome have been described, but clinical data are limited and almost all cases involved young children. Methods We present a detailed clinical description of 13 patients (including six adults) with AUTS2 syndrome who have a pathogenic mutation or deletion in AUTS2. All patients were systematically evaluated by the same clinical geneticist. Results All patients have borderline to severe ID/developmental delay, 83–100% have microcephaly and feeding difficulties. Congenital malformations are rare, but mild heart defects, contractures and genital malformations do occur. There are no major health issues in the adults; the oldest of whom is now 59 years of age. Behaviour is marked by it is a friendly outgoing social interaction. Specific features of autism (like obsessive behaviour) are seen frequently (83%), but classical autism was not diagnosed in any. A mild clinical phenotype is associated with a small in-frame 5′ deletions, which are often inherited. Deletions and other mutations causing haploinsufficiency of the full-length AUTS2 transcript give a more severe phenotype and occur de novo. Conclusions The 13 patients with AUTS2 syndrome with unique pathogenic deletions scattered around the AUTS2 locus confirm a phenotype–genotype correlation. Despite individual variations, AUTS2 syndrome emerges as a specific ID syndrome with microcephaly, feeding difficulties, dysmorphic features and a specific behavioural phenotype.